Saturday 17 October 2026 Export TLPH’s income statement to Excel — free account

Talphera, Inc.

TLPH Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, revenue fell 99.6%, EPS grew 40.0% and free cash flow fell 33.1%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years; insiders bought in the last twelve months.

1.08 0.01 +0.93%

Follow TLPH

Alert me

Market cap: $55.5M
P/E: 0.0×
Fwd P/E: −3.1×
Dividend yield: —
F-score: n/a
Altman Z: −20.73
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.30

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	4	1	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 48.93%

Capital & Financial Ratios $m

Market Cap 55.54

Revenue 0.43

Net Income (15.08)

Free Cash Flow (12.27)

Net Debt (17.08)

Current Ratio 4.29

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (3.10)

P/S ratio 191.48

P/B ratio 5.66

Past 5Y EPS Growth —

This Y EPS Growth 41.18%

Next Y EPS Growth (5.00%)

Next Y revenue growth 1,496.43%

Next 5Y EPS Growth 28.04%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 97.57%

10-year low 10-year high

P/B against its own 10 years 77.60%

10-year low 10-year high

EV/Sales against its own 10 years 97.53%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	9	9	20	17
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	12	9	21	18

	2023	2024	2025	Q'26
Payables	1	1	1	0
ST’ Debt	—	—	—	—
Other	—	—	—	—
	5	3	4	4

Compound Annual Growth %

	10y	5y	3y
Sales	(40.71%)	(58.55%)	(78.50%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(6.43%)	0.00%	(7.91%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	0	—	0	—	0
’23	—	0	0	0	1
’22	0	1	1	0	2
’21	1	0	2	0	3
’20	0	3	1	1	5
’19	0	1	1	0	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(4)	—	—	—
’25	(3)	(3)	(3)	(2)	(11)
’24	(3)	(5)	(3)	(2)	(13)
’23	(5)	(5)	(3)	(4)	(17)
’22	(9)	(9)	(5)	(5)	(28)
’21	(10)	(8)	(4)	(8)	(30)
’20	(14)	(10)	(8)	(6)	(39)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(4)	—	—	—
’25	(3)	(3)	(3)	(2)	(11)
’24	(3)	(5)	(3)	(2)	(13)
’23	(5)	(3)	(3)	(4)	(15)
’22	(9)	(9)	(5)	(7)	(30)
’21	(10)	(10)	(4)	(8)	(32)
’20	(14)	(10)	(8)	(8)	(40)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.04)	(0.06)	—	—	—
’25	(0.10)	(0.10)	(0.11)	(0.06)	(0.34)
’24	(0.16)	(0.15)	(0.13)	(0.07)	(0.50)
’23	(0.75)	(0.40)	(0.08)	(0.25)	(1.29)
’22	(1.20)	9.60	(0.94)	(1.00)	5.72
’21	(1.60)	(1.60)	(1.40)	(1.20)	(5.80)
’20	(4.00)	(1.60)	(2.00)	(2.00)	(9.40)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	48.00	31.00	33.00	32.80	14.00	9.20	1.76	0.43	0.50	0.38	Analyst estimates 2026–2028 Powerpack
	High	90.00	115.00	101.00	81.80	42.80	58.80	13.00	2.78	1.61	1.57
People
People	Employees	39	41	61	99	54	43	19	15	13	12
	Revenue/emp, $m	0.45	0.20	0.04	0.02	0.10	0.07	0.09	0.04	0.00	0.00
Income, $m
Income, $m	Revenue	17	8	2	2	5	3	2	1	—	0
	Gross margin, %	29.05	(33.32)	(84.84)	(197.34)	(11.37)	(33.18)	(46.30)	100.00	—	100.00
	EBT	(43)	(52)	(47)	(53)	(40)	(35)	59	(10)	(13)	(14)
	EBT margin, %	(248.84)	(653.02)	(2,191.86)	(2,325.78)	(745.48)	(1,245.35)	3,339.24	(1,580.18)	0.00	(51,296.43)
	Net income	(43)	(52)	(47)	(53)	(40)	(35)	48	(18)	(13)	(14)
	Depreciation	2	2	1	2	2	2	2	0	0	0
Per share, $
Per share, $	Revenue	7.66	3.41	0.74	0.58	1.27	0.47	0.24	0.05	0.00	0.00
	Earnings	(19.00)	(22.00)	(16.20)	(13.40)	(9.40)	(5.80)	5.73	(1.29)	(0.50)	(0.34)
	Cash flow	(12.97)	(12.70)	(9.96)	(12.93)	(9.03)	(5.01)	(3.84)	(1.23)	(0.49)	(0.27)
	Capex	(1.64)	(1.03)	(0.28)	(0.88)	(0.44)	(0.30)	(0.28)	0.18	0.00	0.00
	Free cash flow	(14.62)	(13.72)	(10.24)	(13.80)	(9.47)	(5.31)	(4.11)	(1.04)	(0.49)	(0.27)
	Book value	(2.36)	(15.57)	1.46	(10.46)	(13.08)	(5.99)	2.95	0.99	0.31	0.40
	Shares, m	2	2	3	4	4	6	7	14	26	42
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.34	0.00	—	0.00
	P/S	6.66	12.02	62.73	72.99	19.52	23.82	9.26	11.69	—	113.49
	P/B	0.00	0.00	31.73	0.00	0.00	0.00	0.75	0.75	—	2.84
	EV/Sales	3.27	6.85	19.16	55.08	15.64	12.17	2.27	8.34	—	80.58
	EV/FCF	(1.71)	(1.70)	(1.38)	(2.31)	(2.10)	(1.08)	(0.13)	(0.51)	—	(3.93)
Cash, $m
Cash, $m	Operating cash flow	(29)	(30)	(29)	(51)	(39)	(30)	(28)	(17)	(13)	(11)
	Capex	(4)	(2)	(1)	(3)	(2)	(2)	(2)	3	—	—
	Free cash flow	(33)	(32)	(30)	(55)	(40)	(32)	(30)	(15)	(13)	(11)
Balance, $m
Balance, $m	Working capital	79	50	92	58	29	32	11	7	7	17
	Total debt	22	19	12	25	22	14	5	—	—	—
	Net debt	(59)	(41)	(94)	(41)	(21)	(33)	(15)	(9)	(9)	(20)
	Shareholders’ equity	(5)	(37)	4	(41)	(56)	(36)	22	14	8	17
Returns, %
Returns, %	ROA	(37.89)	(58.68)	(48.09)	(50.25)	(51.23)	(48.69)	67.52	(54.20)	(67.32)	(59.60)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	(246.80)	(223.45)	0.00	0.00
	ROE	(310.75)	246.18	292.34	286.51	83.11	76.60	(601.31)	(102.44)	(117.65)	(114.16)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CLVR Clever Leaves Holdings Inc.	$96.5M	— (loss-making)	— (loss-making)	+5.36% (above 0%: growing)	n/m	+70.31% (above 0%: growing)	(7.46%)	(105.91%)	Compare
CTOR Citius Oncology, Inc.	$69.4M	— (loss-making)	—	—	n/m	0.00%	67.07%	(583.53%)	Compare
TLPH Talphera, Inc.	$55.5M	— (loss-making)	— (loss-making)	−99.60% (below 0%: shrinking)	n/m	−33.11% (below 0%: shrinking)	100.00%	0.00%
INCR InterCure Ltd.	$55.1M	8.8×	— (loss-making)	−6.53% (below 0%: shrinking)	n/m	+389.50% (above 0%: growing)	32.04%	0.00%	Compare
ZYBT Zhengye Biotechnology Holding Limited	$44.6M	—	—	—	—	−69.31% (below 0%: shrinking)	—	—	Compare
SCYX SCYNEXIS, Inc.	$38.9M	— (loss-making)	— (loss-making)	−8.56% (below 0%: shrinking)	n/m	−98.60% (below 0%: shrinking)	100.00%	(3,308.51%)	Compare
IXHL Incannex Healthcare Inc.	$36.1M	— (loss-making)	— (loss-making)	−92.31% (below 0%: shrinking)	n/m	+327.73% (above 0%: growing)	100.00%	0.00%	Compare
RMTI Rockwell Medical, Inc.	$32.2M	— (loss-making)	— (loss-making)	+10.63% (above 0%: growing)	n/m	−12.92% (below 0%: shrinking)	18.24%	(5.97%)	Compare
CPHI China Pharma Holdings, Inc.	$31.3M	— (loss-making)	— (loss-making)	−7.56% (below 0%: shrinking)	n/m	−113.57% (below 0%: shrinking)	8.82%	(150.99%)	Compare
Median of peers	$41.7M	—	—	−7.04%	—	−6.46%	32.04%	(105.91%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Talphera, Inc. (TLPH) key facts

Talphera, Inc. (TLPH) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, TLPH traded at $1.08, a market capitalization of $55.5 million.
Return on equity was −114.2% and debt-to-equity 0.00.
Its Altman Z-score is −20.73 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.